News

Patent license agreement with NIH

관리자 │ 2023-01-17

HIT

503

Aevisbio and NIH signed the patent license agreement in relation to the development of thalidomide analogues for the treatment of neurological disorders. In accordance of CRADA, Aevisbio and NIH will collaborate to develop the thalidomide analogues in pre-clinical and clinical stages.  


Previous Post Korean Government grant awarded from NRF
Next Post AevisBio entered into a collaborative research with NCI